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A problem many can agree onis the task of feeding a rapidly
expanding world population.Although methods for intense cultivation of
farmland will continue to improve, increasing efficiency of food animal
production willplay a vitalrole as the demand for meat and milk
continues.Dairy and beef cattle operations in the United States are
aware of several management concepts includingnutrition and feeding,
environment and housing, herd health, and genetics and breeding.Basic
laboratory research results play an often subtle but vital role on the
path to economic efficiency and,as available technologies improve,
contribute to efficient food production.Before an applicable technique,
such as embryo transfer in cattle, can be utilized to its full potential,
detailed information about bovine embryo structure and function must be
made available.Plasminogen activator production may be involved in
early developmental events in the bovine and studies of this phenomenon
mayprovideinsightinto measuresaimedatimprovingreproductive
efficiency.This research was conducted in an effort to provide at least
one more byte of information to the ever-expandingfield of bovine embryo
physiology.
A.R. Dyk
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Introduction
Plasminogen activators (PA) are serine proteases that convert the
plasma zymogen, plasminogen, to plasmin, which is an enzyme active in
clot lysis (Christman et al., 1977).Plasminogen activators are classed
into two groups based on molecular weight (MW):urokinase-type PA (uPA)
and tissue-type PA (tPA).Urokinase-type PA exhibit MW between 30 and
55 kiloDaltons (kD), whereas tPA are approximately 72 kD (Dano et al.,
1985).Plasminogen activator is produced by mouse embryos in a biphasic
manner in which the first phase corresponds toimplantation and the
second phase to embryonic cellmigration during tissue remodelling
(Sherman et al., 1976; Strickland et al., 1976).Using a technique known
aszymography,Marottietal.(1982)observedthat mouse parietal
endoderm produced a tPA whereas visceral endoderm and extraembryonic
mesodermproducedanuPA. Inbovineembryos,PAproductionis
undetectable until the blastocyst stage, increases during blastocoelic
expansion and hatching and remains elevated after hatching (Menino and
Williams,1987).Evaluation of the type of PA produced by bovine
blastocysts may provide information about biochemical events associated
with embryo development in this species.Therefore, the objective of
this research was to identify the tissue source and type of PA produced
by bovine blastocysts.2
Review of Literature
Historical Perspective of Plasminogen Activator
Plasminogen activators(PA)areserine proteases that convert
zymogen plasminogen to protease plasmin.Historically, the roles of
plasminogen, plasmin and PA are traced to blood clot lysis when early
researchers noted that under certain conditions blood clots dissolved
spontaneously and could not be reformed (as reviewed by Christman et al.,
1977). Inthe circulatory system,thrombin converts fibrinogen to
fibrin, which is then deposited as fine filamentous proteins entangling
red and white blood cells and platelets, hence, forming a clot.Plasmin
is the protease responsible for the degradation of fibrin in blood and
renal tubule clots (Guyton, 1986).
By the turn of the twentieth century, scientists realized blood clot
lysis was due to fibrinogen or fibrin being proteolytically converted to
a form no longer able to clot blood, but at that time enzymes responsible
for this conversion could not be identified.As early as 1933, Tillet
and Garner identified streptokinase, a streptococcal enzyme, as having
fibrinolytic activity in human plasma.In 1945, Christensen demonstrated
that plasma contains the inactive serum zymogen, profibrinolysin or
plasminogen, which can be converted to the active protease, fibrinolysin
or plasmin,by streptokinase. Theseinitialobservationsinspired
research to investigate systemic PA and the possibility of an alternative
mechanism for regulating fibrinolysis via plasminogen activation to
plasmin.Some of the early reports on fibrinolysis in blood clotting3
were contradictory due to the difficulties involved in isolating and
purifying components of the plasmin system.
Plasminogen activators have been identified in almost all tissues
and tissue extracts, in vascular endothelium, in blood and in many body
fluids, including urine (Christman et al., 1977; as reviewed by Dano et
al., 1985).Such a wide distribution of PA led to the hypothesis that
fibrinolysis was crucial to many aspects of cellular maintenance in the
intactorganism,including: vascularization during woundhealing,
inflammation and tumor infiltration.As early as 1947, it was suggested
that cultured cancer cells released an enzyme that activated plasminogen
to plasmin.However, due to the later-discovered broad specificity of
PAandplasminandthefailureto makeadistinctconnectionto
malignancy,interestinfibrinolyticproteolysisandplasminogen
activation in cancer waned (Dano et al., 1985).The 1970's saw a renewed
interestinPA and cancer whenit was shown that transformation of
cultured cells by a variety of oncogenic viruses consistently induced a
drastic increase in extracellular proteolytic activity, due mainly to the
release of PA from the transformed cells (Ossowski et al., 1973a,b, 1974;
Quigley et al., 1974; Unkeless et al., 1973, 1974).Since then, many new
purification techniques have been developed and the results reaffirm that
PA plays a role in tissue degradation and maintenance in the normal
organism as well as in cancer (Dano et al., 1985).
With an historical synopsis of PA and the plasmin system in mind,
thebiochemicalcomponentsandmechanismsinvolvedinplasminogen
activation can be discussed.Such a review willprovide the basic
biochemistry needed to understand the physiologic functions of PA in4
classical clot lysis and cancer, as well as its role in reproduction and
embryonic development.
Classification of Plasminogen Activators
According to Christman et al.(1977) vertebrate PA were formerly
divided into several groups:circulating plasminogen activators found
in blood, tissue plasminogen activators, urinary plasminogen activators
(urokinase) and tissue culture plasminogen activators.More recently,
however,PA are classed into two main groups based primarily on MW
observations:urokinase-type PA (uPA) and tissue-type PA (tPA; Dano et
al., 1985).Other notable differences between the two PA types may be
made according to exact function or immunological reactivity; however,
the present focus will concentrate on the MW categorization of PA.They
arerespectivelytermeduPAandtPAbecausethey wereoriginally
identified in urine and tissue extracts.
The molecular weight of uPA falls in the 30-55 kD range because
urokinase exists in two proteolytically active forms with MW of 31.5 and
54.7 kD as determined by sedimentation-equilibrium methods (White et al.,
1966); whereas the molecular weight of tPA is approximately 70 kD (Binder
etal.,1979;Dano etal.,1985). Differencesinamino acid and
correspondingcomplementary deoxyribonucleicacid(cDNA)nucleotide
sequences have shown bothtypes ofPA tobeseparate productsof
independent genes(Dano etal.,1985). Advancesinisolation and
purification of mammalian plasmin system components have allowed more
detailed studies of the enzymology and characterization of plasminogen
activation.5
Biochemistry of Plasminogen Activation
Plasminogenandplasminbiomoleculesareforthemostpart
homologously conserved acrossat least severalmammalian speciesin
regard to terminalamino acid sequences and MW,suggesting similar
proteolytic cleavages are involved in the activation of all plasminogens
(Robbins et al., 1973; Summaria et al., 1973; Christman et al., 1977).
Human plasminogen activation has been quite extensively studied because
it plays an important role in clinical medicine.Isolated, intact and
undegradedhumanplasminogen,termedGlu-plasminogen,isasingle
polypeptide chain with an approximate molecular weight of 92 kD having
aglutamic acid(Glu)residueat the amino(NH2-)terminus andan
asparagine (Asn) residue at the carboxyl(COON -) terminus (Figure 1;
Robbins etal.,1967,1973;Christman etal.,1977). Plasminogen
activator catalyzes the cleavage of a sensitive single arginine-valine
peptide bond in Glu-plasminogen to form the active protease Glu-plasmin,
consisting of two polypeptide chains held together by a single disulfide
bond. Alternatively,ithasbeen suggested Glu-plasminogen can be
convertedtoanother onechainform called Lys-plasminogenby the
cleavage of a lysine-lysine bond, resulting in liberation of a7kD
"activation peptide."Lys-plasminogen is then converted to two-chain
Lys-plasmin by hydrolysis of the same arginine-valine bond as in Glu-
plasminogen.Autocatalysis by plasmin allows for the conversion of Glu-
plasmin to Lys-plasmin (Dano et al., 1985).C'
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Figure 1. Representative drawing of human Glu-plasminogen. Arrow I indicates site of bond cleavage
to form plasmin.Arrows 2 and 3 show points of possible activation peptide removal. al7
Urokinase was extensively studied and commonly used in the first
plasminogen activation studies.Kinetic studies have shown a possible
sequence of plasminogen activation by urokinase as depicted in Reaction
Sequence I:
I
(1) Glu-plasminogen > Lys-plasminogen + "Activation Peptide"
92 kD 86 kD 7 kD
urokinase
(2) Lys-plasminogen > Lys-plasmin
63 kD 25 kD
(heavy chain) (light chain)
Controversy existed as to whether Reaction (1) could be catalyzed by both
urokinase and plasmin or only by plasmin, and as to whether Reaction (1)
occurs before enzymatically active plasmin is formed.Alternatively,
Reaction Sequence II suggested another pathway:
II
urokinase
(3) Glu-plasminogen >Glu-plasmin
92 kD 70 kD 25 kD
(heavy chain) (light chain)
(4) Glu-plasmin > Lys-plasmin + "Activation Peptide"
63 kD----25 kD 7 kD
(heavy chain)(light chain)8
However, Reaction Sequence II had never resulted in detectable amounts
of Glu-plasmin.In Reaction SequenceI,once any plasmin is formed
either at low efficiency by urokinase or existing asa plasminogen
contaminant, plasmin removes the activation peptide.It was suggested
Glu-plasminin Reaction SequenceII may exist transiently and could
catalyze activation peptide removal from Glu-plasminogen to form the
predominantly found Lys-plasmin.Conversion of Lys-plasminogen to Lys-
plasmin seemed to occur much more rapidly than that of Glu-plasminogen
to Lys-plasmin (Christman et al., 1977)
Although it had been concluded that Reaction Sequence I was most
likely the case for plasminogen activation by urokinase, more recent
evidence indicates otherwise for in vivo systems.Holvoet et al. (1985)
described a murine monoclonal antibody specific for Lys-plasminogen and
Lys-plasmin-a2-antiplasmin complex, but not specific for Glu-plasmin and
Glu-plasmin-a2-antiplasmin.Using this antibody,it was shown under
physiological conditions that plasminogen activation yields the Glu-
plasmin-a2-antiplasmin complex, indicating the direct cleavage of the
arginine-valine peptide bond in Glu-plasminogen and refuting the concept
of Lys-plasminogen intermediate formation.Thus, Reaction Sequence II
may be the correct sequence for the activation of human plasminogen.
Plasmin
Regardless of activation sequence, once active plasmin is formed it
consists of two polypeptide chains held together by a disulfide bond.
Plasmin resulting from activation of either Glu-or Lys-plasminogen9
consists of a heavy chain (63 kD) and a light chain (25 kD; Sodetz et
al., 1972; Christman et al., 1977).The light chain contains the active
site and has amino acid sequence homologies similar to other serine
proteases such as trypsin and chymotrypsin (Dano et al., 1985).Plasmin
hasbroad trypsin-like specificity hydrolyzinglysineandarginine
peptide bonds in several proteins, some of which include casein (Remmert
and Cohen,1949),cell membrane proteins (Lazarowitz et al.,1973),
immunoglobins and blood-clotting factors V, VII and XIIa (Christman et
al., 1977).
Two seemingly important inhibitors of plasmin are a2-macroglobulin
and a2-antiplasmin.Other strong plasmin inhibitors include bovine
pancreatic trypsin inhibitor, lima bean trypsin inhibitor and soybean
trypsin inhibitor (Dano et al., 1985).
Urokinase-Tvpe Plasminogen Activator
Besides urine, uPA has been isolated from human blood and seminal
plasma, malignant prostate tissue and from several sarcoma cellline
culture fluids (Dano et al., 1985).Human urokinase and uPA have been
collectively categorized asfar asMWisconcerned. Each form of
urokinase has a specific MW (31.5 and 54.7 kD), and any uPA in general
is categorized as exhibiting MW between both human urokinase forms.
Thus, the terms urokinase and uPA willbe used synonomously in this
section.
Urokinase-type PA exists in a single-chain form (scuPA) and in a
two-chain form (tcuPA). In1979,scuPA was identified as having a10
molecular weight of about 54 kD, and it was indicated to be the actual
precursor to active tcuPA with little intrinsic activity.However, the
catalytic efficiency of scuPA against plasminogen asa substrate was
later reported to be kinetically equivalent to that of tcuPA (Gurewich,
1987).Hence, scuPA was not considered to be a true zymogen (Collen et
al., 1986).More recent evidence supports the contrary.Petersen et al.
(1988) have reinvestigated this issue and have legitimately concluded
that scuPAisindeedaproenzyme form of tcuPA with little or no
intrinsic acitvity.Nonetheless, tcuPA contains an "A-chain" or "light
chain" (20 kD) and a "B-chain" or "heavy chain" (30 kD); the chains are
bridged by a disulfide bond.Molecular weights of both chains vary among
speciesand sample preparation techniques.The A-chain containsa
"kringle" structure and an "epidermal growth factor domain", whereas the
B-chain is actually the structurally conserved region of the molecule
possessing the serine protease active site.Limited proteolysis by
plasmin can cause cleavage of scuPA between the A- and B-chains into
active tcuPA, and is followed by part of the A-chain being removed.The
complete amino acid sequence of human tcuPA has been elucidated, and the
nucleotide sequence of porcine uPA strongly suggests close homology among
species.Human, pig and mouse cDNA and messenger ribonucleic acid (mRNA)
for uPA have been identified and characterized (Figure 2; Dano et al.,
1985).
Although plasminogenis the most documented substrate for uPA,
studies have shown uPA to hydrolyze low MW substrates with amide and
ester derivativesof arginineandlysine and an extracellular matrixEpidermal Growth
Factor Domain
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Figure 2. Skeletal molecular sketch of single-chain urokinase-typeplasminogen activator.
Dashed line indicates point of limited proteolysis to yield'SPA.12
protein.Species specificity of uPA exists to some degree with respect
to plasminogen. For example,chicken uPA has no activity on human
plasminogen, but human uPA may inefficiently activate chicken plasminogen
(Dano et al., 1985).
Inhibitors of uPA include:diisopropyl flourophosphate (DFP) which
irreversibly binds to the serine active site; zinc (2+); some rare earth
metals;and a-tocopherol. Some plasmin inhibitors,suchasbovine
pancreatic trypsin inhibitor and soybean trypsin inhibitor do not inhibit
uPA. Urokinase-type PA specifically catalyzes arginine-valine bond
hydrolysis in plasminogen, hence, arginine and L-arginine methyl esters
are effective uPA inhibitors.Physiological concentrations of sodium
chloride have been demonstrated to inhibit uPA, the effect being exerted
through a suggested inhibitor of PA and plasminogen.Sodium chloride
does not inhibit plasmin activity (Dano et al., 1985).
A major breakthrough wasthe determination of uPA amino acid
sequences in comparison to those of tPA, and the resulting indication
that both types of vertebrate PAs are definitely different gene products.
Tissue-Type Plasminogen Activator
Tissue-type PA hasbeen purified from various tissue extracts
including:porcine heart, kidney and ovary, human uterine tissue, blood,
plasma and cell culture fluids, and several tumor cell lines (Dano et
al., 1985).Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) has revealed the mean MW of human tPA to be approximately 70-
75 kD (Binder et al., 1979; Dano et al., 1985).Thus, for classification13
purposes, PA exhibiting MW significantly higher than the range for uPA
are classed as tPA.
Similar to uPA, tPA also exists in a single-polypeptide chain form
(sctPA)and ina two-polypeptide chain form (tctPA). The tentative
conclusion that sctPA may be an inactive zymogen should be approached
with caution because some reports on the enzyme activity of sctPA, like
that of scuPA, are conflicting.Two-chain tPA contains an "A" or "heavy"
chain (40 kD) and a "B" or "light" chain (30 kD), both linked together
by a disulfide bond.The A-chain contains two "kringle" structures, an
"epidermal growth factor domain", and a "fibronectin finger domain",
whereas the B-chain contains the serine protease responsible for its
plasminogen-activating capacity.Single-chain tPA is converted to tctPA
by limited plasmin proteolysis or other contaminating proteases during
assay which cleave an arginine-isoleucine peptide bond between the A- and
B-chains(Figure3;Danoetal.,1985;Lijnenand Collen,1987).
Complete amino acid and cDNA nucleotide sequences for human tPA have been
determined (Edlund et al., 1983; Pennica et al., 1983; Degen et al.,
1986).
The only knownsubstrate for tPAisplasminogen;unlike uPA,
however, tPA has a strong affinity for fibrin which actually stimulates
plasminogen activation by tPA.Arginine chloromethylketone, p-nitro-
phenol-p-guanidinobenzoate and DFP are inhibitors of tPA.As with uPA,
bovine pancreatic trypsin inhibitor and soybean trypsin inhibitor do not
inhibit tPA activity.Because different in vitro assay techniques have
been used among uPA and tPA, it should be noted that complications exist
when comparing the two PA types (Dano et al., 1985).Fibronectin
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Figure 3. Skeletal molecular sketch of single-chain tissue-type plasminogenactivator.
Dashed line indicates point of limited proteolysis to yield tPA.15
Other Plasminogen Activators
InadditiontouPAandtPA,otherknownPAinclude: 1)
Streptokinase, a streptococcal protein that has a mechanism of action
much different from that of vertebrate PA; 2) serum kallikrein; and 3)
blood coagulation factors XI and XII, the latter two exhibiting very
little activity.A PA identified as a serine protease contained in outer
membranes of two Escherichia Coli strains has been identified (Dano et
al., 1985).In 1982, Harvey and coworkers reported a lung cancer cell
line that secretedaPA havinga MW of over 1,000kD. ThisPA,
consisting of disulfide-linked oligomers, also had the capacity to bind
anti-uPA antibodies.
Although most of the literature and research on PA is directly
linked to clinical medicine and hematology, several reports have alluded
towards a role for PA in reproduction (Strickland, 1980).Ovaries from
the pregnant pig were identified as a source of tPA as early as 1969 (Kok
andAstrup,1969). Theinvolvementof plasminogenactivationin
ovulationwaslaterdescribedbyBeers(1975),andinthecow
nonetheless!
Plasminogen Activator in Male Reproduction
A variety of cells and tissues produce PA,some of which are
directly involved in reproduction.In rats, Sertoli cells that line
seminiferous tubulesandnourish developingspermatidsproduceand
secretePA(Strickland,1980). Lacroix etal.(1977,1981)have
postulated PA involvement in localized proteolysis during seminiferous16
tubule restructuring when early prophase spermatocytes are translocated
from basal to adluminal compartments, and in spermiation during stages
VII and VIII of the cycle of the seminiferous epithelium.Marzowski and
coworkers (1985) demonstrated the existence of a Sertoli cell membrane-
associated PA(38-40kD)that may function to restructure membrane
components at cell cell interfaces, whereas the secreted PA form may
act fibrinolytically in the seminiferous epithelium.Cultured Sertoli
cells will secrete increased amounts of a tPA (70 kD)in response to
dibutyrylcyclicadenosinemonophosphate(dbcAMP)andfollicle-
stimulating hormone (FSH; Lacroix and Fritz, 1982), whereas under basal
conditions an uPA (45-48 kD) is primarily secreted (Hettle et al., 1986).
These findings led Hettle et al. (1986) to postulate the association of
PA with migration of Sertoli cell cytoplasmic extensions between the
basal lamina and preleptotene spermatocytes.Immunohistochemical and
zymographic studies enabled Vihko et al. (1988) to detect both uPA and
tPA activity at different stagesinthe cycle of the seminiferous
epithelium. Tissue-typePA activity hasalso been demonstratedin
seminalplasma,butno correlation exists between PA and fertility
(MacGregor et al., 1987).
Plasminogen Activator in Female Reproduction
In the mammalian female, PA, plasmin and collagenase are involved
in ovulation, where plasmin is thought to participate in follicle wall
breakdown (Beers et al., 1975; Strickland, 1980; Reich et al., 1985).
However, Shimada et al.(1983) indicated that prostaglandins were not
involved in the preovulatory synthesis of PA and PA was not involved in17
follicular wall rupture.They suggested alternative roles for PA during
ovulation,suchascumuluscelldetachmentandgranulosacell
proliferation.Gonadotropins stimulate release of a tPA (80 kD) from
cultured rat ovarian granulosa cells, whereas uPA (40 kD) release is not
affected. Inaddition,anidentified inhibitor of fibrinolysisis
suppressed by FSH and luteinizing hormone (LH; Ny et al.,1985).At
ovulation, hormonally stimulated rat granulosa cells produce only tPA
whereasthecalcellsarethe major source ofuPA. Ahypothesis
explaining the ovulatory mechanismisthat thecalcelluPA may be
involved with follicle wall rupture, and tPA from granulosa cells may be
essential for immediate blood clot fibrinolysis and follicular fluid
proteoglycan degradation (Canipari and Strickland, 1985).In the mouse,
mRNA probes for uPA have been used to demonstrate that granulosa cells
producemainlyuPAratherthantPA(Caniparietal.,1987).
Interestingly, equivalent ovarian follicular cells from very closely
related species express two perhaps functionally similar yet genetically
different enzymes.
Fibrinolytic activity in uterine flushings has been attributed to
aPA(Kwaanand Albrechtsen,1966) which appears tobe hormonally
regulatedintherat(Katzetal.,1976). Estrogenstimulates
plasminogen uptake by the mouse uterus suggesting a mechanism by which
uterine plasminogen levels canbeincreased(Finlay etal.,1983).
Plasminogen in the porcine uterus exists presumably as a serum transudate
and may serve as a substrate for PA produced by pig blastocysts (Mullins
et al.,1980; Fazleabas et al.,1983).Although a specific role for18
uterine PA has not been established, the enzyme may be involvedin
maternal-embryonic interactions.
Soon after ovulation, the female gamete, or oocyte, becomes a free-
floating entity within the Fallopian tube or oviduct.Although the
oocyte remains surrounded by an acellular glycoprotein matrix, the zona
pellucida, prior to and after fertilization, a number of mRNA transcripts
willremainstoreduntilspecificdevelopmentaleventsrequire
expression.Mouse and rat primary oocytes and zona pellucida-denuded
fertilized eggs do not contain PA, whereas ovulated secondary oocytes
contain a tPA (Huarte et al., 1985).After the resumption of meiotic
maturation in primary oocytes, tPA mRNA undergoes a structural change
referred to as "polyadenylation" at the 3' end of the molecule (Huarte
et al., 1987).This allows for the possible translation and production
of tPA at fertilization; however, tPA activity is not expressed again
until after Day 6 of mouse embryo development (Strickland et al., 1976;
Huarte et al., 1985, 1987). Although the exact role(s) of tPA in the
oocyte has not been completely defined, Huarte et al. (1985, 1987) have
suggested its involvement in fertilization and in the zona reaction,
which blocks the phenomenon known as polyspermy.Liu and Hsueh (1987)
have suggested tPA activity may be related to cumulus cell expansion and
dispersion.
A review of early mammalian embryo development is included mainly
with reference to the bovine; however, other species are included for
comparison or contrast when necessary.19
Aspects of Early Mammalian Embryo Development
If after ovulation the oolemma is penetrated and the oocyte is
fertilized by a viable spermatozoan, the "activated" oocyte undergoes
maturation and completion of meiosis with the release of polar bodies
into the perivitelline space.Fertilization normally takes place in the
ampullary-isthmic junction of the oviduct, after sperm have had ample
time for capacitation.Any remaining corona radiata cells are shed from
the zona pellucida.The resulting one-cell embryo or zygote undergoes
a series of mitotic divisions, or cleavages, and morphological changes
leading up to establishment of pregnancy and fetal development (Bazer et
al, 1987; Betteridge and Flechon, 1988).
First cleavage of the zygote into two separate embryonic cells,
called blastomeres, occurs approximately one day post-fertilization for
most mammals.Several cellular features characteristic of mammalian
embryo cleavage distinct from lower animal forms include:
1)cleavage occurs at a much slower rate;
2)"rotational cleavage" exists in which the first cleavage is a
normal split, but remaining cleavages occur in different patterns
between the first two blastomeres;
3)Although initial cleavages occur simultaneously, synchronization
is eventually lost and blastomeres begin dividing independently
of each other; and,
4)the phenomenon of "compaction" where after the eight-cell stage
(third cleavage) blastomeres huddle together into a mulberry
shape, called the "morula" stage (Gilbert, 1985).20
The zona pellucida plays animportant rolein livestock embryo
development through the morula stage, which is approximately Day 5 of
development in the bovine.The embryo enters the uterus at about this
time.In addition to keeping blastomeres together, the zona pellucida
may function to conserve the microenvironment of the perivitelline space,
the space between the zona pellucida and the oocyte (Betteridge and
Flechon, 1988).The zona pellucida is a very important component in the
block to polyspermy immediately following the cortical reaction observed
during fertilization (Bazer et al., 1987).
While yet contained within the space of the intact zona pellucida,
blastomeres of the compacted morula develop tight intercellular junctions
followedbyfluidaccumulationintoacentralcavitycalledthe
blastocoele.This marks conversion to the early blastocyst stage on
approximately Day 7 of bovine development.With asynchronous cleavage
blastomeres become unequal in size and differentiate into two distinct
cell populations.Larger blastomeres comprise the majority of cells
forming the outside peripheralcuboidallayer termed trophoblast or
trophectoderm.The outer portion of the placenta, the chorion, is later
formed from trophoblast.A group of smaller blastomeres residing within
the embryo and surrounded by trophectoderm forms the inner cell mass.
The inner cell mass will later develop into three primary germ layers
(ectoderm, mesoderm, endoderm) during the process of gastrulation.The
distinction between trophectoderm and inner cell mass represents the
firstdifferentiativeeventinmammalianembryodevelopment. On
approximately Day 8, endoderm cells spread out from beneath the inner
cell mass and by Day 10 completely line the trophectoderm surrounding the21
blastocoele, forming the trophoblast (Gilbert, 1985; Bazer et al., 1987;
Betteridge and Flechon, 1988).
The bovine blastocyst will divest itself of the zona pellucida during
the process of hatching between Days9and10 of development. In
rabbits,zonapellucidadissolutionoccursviablastolemmase, a
trophoblastic enzyme.The mouse blastocyst rhythmically expands and
contracts (Bazer et al., 1987), and Perona and Wassarman (1986) suggested
limited proteolysis by a trypsin-like proteinase, strypsin, is involved
in hatching.A uterine or embryonic enzymatic factor may be involved
in changes in the integrity of the porcine zona pellucida, and hence may
contribute to the hatching process (Menino and Wright, 1982; Broermann
et al., 1989).Expansion and contraction caused by hydrostatic pressures
in the bovine blastocyst play a major rolein hatching as the zona
pellucida distends and weakens (Bazer et al., 1987).However, bovine
embryos can activate plasminogen to the active enzyme plasmin, which may
represent a mechanism by which hatchingis facilitated(Menino and
Williams, 1987).
Followinghatching,thebovineblastocystcontinuestoexpand
spherically while blastocoelic fluid accumulation continues.By Day 12,
the inner cell mass ruptures through to the outside of the sphere and is
identified as embryonic disc.Between Days 12-14 the bovine blastocyst
begins to undergo a rapid logarithmic elongation phase.The shape of the
embryo changes from spherical to ovoid during this time, and by Day 14-
16 mesodermal cells from the embryonic disc begin to migrate between the
trophectoderm and endoderm.The bovine blastocyst will have undergone
the morphological change from a 3-mm spherical shape on Day 13 toa 25-22
cm filamentous form on Day 17.By Day 18 of gestation, the blastocyst
has extended into the contralateraluterine horn.This occurs via
hyperplasia of the trophectoderm and endoderm.Days 16 to 19 have been
definedas"critical"forthematernalrecognitionofpregnancy,
presumably due to embryonic signals aimed at the uterus (Bazer et al.,
1987; Betteridge and Flechon, 1988).
Unlike rodents and primatesin which blastocysts penetrate the
uterine mucosa invasively,implantationinruminants occurs through
interdigitation of trophoblast and endometrial microvilli.Placental
attachment begins on approximately Days 28-30, and is completed between
Days 40-45 of gestation in the cow (Bazer et al., 1987).
Studies of early embryonic development using mammalian models have
beenincreasingly focusedatthe biochemicaland molecular levels.
Within the last two decades, roles for plasminogen, PA and plasmin in the
embryo have been speculated and willbe discussed in this literature
review.
Plasminogen Activator in Embryo Development
Rodent Embryos.Fibrinolytic activity due to a PA was first linked
toembryo developmentbyLeidholmand Astedt(1975)intherat.
Fibrinolytic activity wasexhibited by Day1-4rat embryos during
oviductal passage; however, fibrinolysis decreased when embryos entered
the uterus on Day 5 and disappeared at implantation.Rat oviduct and
endometrium also exhibited fibrinolytic activity.Leidholm and Astedt
(1975) postulated that PA prevented the adherence of embryos to fibrin
depositsliningthemucosa,andthesubsequentdisappearanceof23
fibrinolysis following entry into the uterus may be a prerequisite for
the embryo to implant.
Strickland et al. (1976) and Sherman et al. (1976) characterized a
biphasic pattern of PA production in cultured mouse embryos.Using a
fibrin-agaroverlayassaythatalloweddirectvisualizationof
fibrinolysis, PA was first detected in Day 6 embryos.Production of the
protease peaked on approximately Day 8-9 then decreased, representing the
first phase.Second phase of PA production by egg cylinder stage mouse
embryos beganon Day11,peakedonapproximately Day12,and was
maintained until at least Day 15 of in vitro development.Level of peak
PA activity of the second phase was fivefold higher than that of the
first phase.Trophoblast cells were largely responsible for PA secretion
during the first phase, which closely correlated to invasiveness of the
trophoblast in vivo, suggesting a possible role for PA in implantation.
The second phase of PA secretion was mainly due to parietal endoderm,
suggestingthatPAmaybeacontributory mechanisminembryonic
endodermal cell migration and tissue remodelling.Sherman et al. (1976)
suggested PA may also serve as a useful biochemical marker in identifying
certain cell types within the developing mouse embryo; however, Bode and
Dziadek (1979) reported PA secretion to be more widespread in the mouse
embryo, rather than specifically limited to certain tissues.Utilizing
casein and fibrin agar overlays containing purified plasminogen, Bode and
Dziadek (1979) indicated that all tissues (parietal endoderm, visceral
yolk sac endoderm and mesoderm,and amnion)in the Day 7-10 post-
implantation mouse embryo eventually secrete PA, and they concluded that24
PA is consistent in playing a role during rapid embryonic growth and
morphogenetic changes.
Sherman (1980) reported that fibrinolytic activity due to PA in
preimplantation mouse embryos was associated with the zona pellucida.
Sherman (1980) concluded that PA secretion in mouse blastocysts was not
directly associated with hatching or the acquisition of trophoblast cell
adhesivenessandproposedthatPAwasinvolvedwithtrophoblast
invasiveness.Kubo and Spindle (1980) concluded that at least two types
of proteolytic activity are present in mouse blastocysts at the time of
implantation:
1)trypsin-like activity primarily involved in attachment; and
2)fibrinolyticactivityprimarilyinvolved
outgrowth.
Plasminogen activator production was one of several enzymatic parameters
investigated in mouse embryos cultured in various media.Blastocysts
cultured in suboptimal medium produced less PA than blastocysts cultured
in enriched medium (Sellens and Sherman, 1980).
Marotti et al. (1982) investigated the distribution of the PA
in Day 12 mouse embryonic tissues.Marotti et al.(1982) used
criteria to distinguish between the two types of PA produced by
embryonic cells:
1) MW;
2) interaction with serum inhibitors; and
3) antigenic properties.
et al.(1982) utilized SDS-PAGE in combination with a casein-
introphoblastic
Marotti
types
three
mouse
agar underlay technique known as zymography to demonstrate that mouse25
parietal endoderm produced mainly a tPA (79 kD) and visceral endoderm
and extra-embryonic mesoderm produced an uPA (48 kD).Parietal endoderm
tPA was partially affected by acid-treated serum and inhibited by anti-
tPA antibodies.Urokinase-type PA produced by visceral endoderm and
extraembryonicmesodermwasinhibitedbyacid-treatedserumand
immunoprecipitated by anti-urokinase antibodies.Marotti et al. (1982)
suggested that these diagnostic procedures which were capable of distin-
guishing between the two types of PA could be used as biochemical markers
for tracing parietal endoderm during development.As this work dealt.
with quite an advanced embryonic stage, Marotti et al. (1982) suggested
that both types of PA may play roles in cell migration during mouse
embryogenesis.
Menino and O'Claray (1986) reported more mouse embryos completed
hatching, attached to the plastic culture dish substratum, and generated
trophoblasticoutgrowthinplasmin-andplasminogen-supplemented
Whitten's medium than in medium lacking the enzyme or its zymogen.A
caseinolytic agar gelassay validated PA productionin plasminogen-
supplemented medium.A proteolytic as well as a trophic effect may be
enhancing in vitro embryo development in Whitten's medium supplemented
with either plasmin or plasminogen, as compared to medium supplemented
with serum or other proteases, such as pronase and trypsin (Menino and
O'Claray, 1986).
Muchof theresearchinvestigatingtheroleofPAinembryo
development has been performed in the rat and mouse.These animals serve
as useful mammalian models since they are relatively inexpensive to
maintain on experiments and large numbers of embryos can be collected for26
meaningful statistical analysis.However, differences do exist in embryo
and fetal development among the mammalian species.During the 1980's
severalresearch laboratories investigated the involvement of PAin
embryo development in the livestock species.
Porcine Embryos.Mullins et al. (1980) established that expanding
Day 12 porcine blastocysts release significant quantities of PA into the
culture medium.Pig conceptus attachment to the uterine wall occurs
gradually beginning on Day 12 with trophoblast becoming firmly fixed in
position on about Day 18; yet placentation in the pig is not considered
invasive.Pig trophoblast when transplanted to an ectopic site during
the period of uterine attachment becomes invasive (Samuel, 1971; Samuel
and Perry,1972).These observations led Mullins et al.(1980)to
investigate the existence of a PA inhibitor secreted by the endometrium.
Mullins etal.(1980)reported that the porcine uterus produceda
progesterone-induced PAinhibitor which may beinvolvedin damping
blastocyst proteolysis, thereby preventing invasive implantation.
Fazleabas et al. (1983) also reported the production of PA by porcine
embryos.Utilizing an :25I-fibrin plate assay, Fazleabas et al.(1983)
observed that pig embryos released PA in a biphasic pattern similar to
that found in the mouse embryo.The first phase of porcine embryo PA
productiononDays10-12correspondstothetimeofblastocyst
elongation, while the second phase on Days 14-16 corresponds to a period
atwhichembryonic DNAcontentisincreasing markedly. Estrogen
production by the elongating Day 12 pig blastocyst may also trigger the
release of a plasmin inhibitor by the endometrium, hence, restricting
embryonic proteolytic activity due to PA(Fazleabas etal.,1983).27
Plasminogen existing as a serum transudate in the pig uterus may also be
a result of local embryonic estrogen production (Fazleabas et al., 1983).
YolksacdevelopmentbeginsonapproximatelyDay13inthepig
blastocyst, and by Day 16 the yolk sac extends along most of the length
of the conceptus (Perry, 1981).With these observations, Fazleabas et
al. (1983) postulated the first phase of porcine blastocyst PA production
is associated with a period of intense tissue remodelling whereas the
second phase is involved with tissue proliferation.
Bovine Embryos.Bovine embryos cultured with various plasminogen
concentrations were evaluated for developmental stages in vitro, and the
extent of PA production and plasminogen activation was quantified (Menino
and Williams, 1987).Morphologically normal 16-cell embryos and early
morulae were cultured in Ham's F-12 medium with 15 mg/ml bovine serum
albumin(BSA)containinglevelsof0,15,30,60,or120µg /ml
plasminogen (Figure 4).The percentages of bovine embryos developing to
theinitiatinghatchingblastocyst,hatchedblastocyst,attached
blastocyst, and attached blastocyst with trophoblastic outgrowth stages
were not significantly different between the five levels of plasminogen.
However, initiation and completion of hatching accelerated as plasminogen
concentration increased in the culture media.Plasminogen activator and
plasminlevelsintheculturemediaweredeterminedutilizinga
caseinolytic assay.Plasminogen activator production was low for the
first 48 h of culture until the blastocyst stage, increased between 48-
120h during blastocoelic expansion and initiation of hatching,and
tended to remain elevated throughout and after hatching.Plasminogen22
Figure 4.Bovine embryos cultured in Ham's F-12 with 15 mg/ml BSA (x
360). a) Expanding blastocyst cultured for 72 h in medium with
15 µg /ml plasminogen.b) Hatching blastocyst after 120 h in
medium with no plasminogen.29
Figure 4.(ctd.)c) Hatched blastocyst cultured for 120 h in medium with
60 pg/mlplasminogen. d)Attached blastocyst with
trophoblastic outgrowth after 21 d in medium with 15
plasminogen pg/ml plasminogen.30
activation,measuredindirectlyastheplasminconcentrationina
microdrop of medium, followed PA production and was consistently low for
thefirst48-72 hof culture. Embryonicactivationof increased
sharply thereafter, and also plateaued after 120 h (Figure 5; Menino and
Williams, 1987).
Although the mouse embryo does not exert a dose-dependent response
between plasmin or plasminogen level in the culture medium and the per-
centageof embryosattainingaparticularcellstage(Meninoand
O'Claray,1986),bovine embryos indeed exhibit accelerated rates of
initiation and completion of hatching at 120 µg /ml plasminogen than at
thelower experimentalconcentrations. These accelerated ratesof
initiation and completion of hatching may be due to plasmin-mediated
effects on the zona pellucida.Menino and Williams (1987) suggested the
activation of plasminogen to plasmin may be a mechanism utilized by the
bovine blastocyst to "effectasublysis of the zona pellucida" and
thereby facilitate hatching. Interestingly enough,bovine embryos
culturedinmedium containing120µg /mlplasminogenhatchedata
comparative gestational age of 10 to 12 days (Menino and Williams, 1987),
closely approximating the observedinvivo range of7to10days
(Betteridge and Flechon, 1988).42)
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Figure 5.Plasminogenactivator productionby bovine embryos cultured in Hams I2 with 15 mg/ml BSA
blastocyst, initiating hatching bastocyst, h-hatched blastocyst).
(taken From MeninoandWilliams,1987; used with b.blastocyst,32
Ovine Embryos.Plasminogen activator production by early ovine
embryos has recently been documented by Menino et al.(1989).Menino
et al.(1989) speculated that the conversion of uterine plasminogen to
plasmin by the secretion of PA may be a mechanism utilized by the ovine
blastocyst to cause a sublysis of the zona pellucida and facilitate
hatching.Embryonic PA production was quantified and the effects of
various levels of plasminogen on in vitro development and zona pellucida
integrity were evaluated.
More ovine embryos hatched in medium containing 60 and 120 µg /ml
than0 µg /m1plasminogen. Zona pellucida dissolution timeinan
acidified phosphate buffered saline was less after incubation in medium
with 60 and 120 mg/m1 plasminogen than 0 Ag/m1 plasminogen; however, a
solubility changein the zona pellucida occurredinthe absence of
plasminogen or plasmin.Plasminogen activator production was low until
the morula stage,increased during morula-blastocyst transition and
remained elevated throughout blastocoelic expansion and hatching.Zona
pellucida solubility, PA production and plasminogen conversion to plasmin
increased with advancement of embryonic stage; however, PA production and
plasminogenconversiontoplasmin were poorly correlated with zona
pellucida solubility.Menino et al. (1989) suggested that other factors
may play a role in changing zona pellucida integrity prior to hatching
such as physical forces resulting from blastocoelic expansion or even
other as yet unidentified enzymes.33
Materials and Methods
Embryo Collection and Culture
Twenty-two Holstein cows from the Oregon State University dairy herd
were estrous synchronized with prostaglandin F2,(PGF2a; Lutalyse, The
Upjohn Co.,Kalamazoo,MI)andsuperovulated with porcine follicle
stimulating hormone (pFSH: Sigma Chemical Co., St. Louis, MO).Two 25-
mg injections of PGF2a were administered i.m. 12 d apart(Day 0 = first
PGF2a injection) to all 22 cows.All cows received twice daily injections
of pFSH i.m. at dosages of 6, 5, 4 and 3 mg on Days 10, 11, 12 and 13,
respectively.Estrus detection was conducted starting 12 h after the
second PGF2a injection and at 12-h intervals thereafter.Visual detection
of cows in standing estrus was facilitated by utilizing a vasectomized
bull or livestock paint on the tailhead.Cows observed in estrus were
artificially inseminated with 1 or 2 straws of frozen bull semen at 0,
12, and 24 h after onset.Twelve to fourteen days after onset of estrus,
hatched blastocysts were collected at slaughter by flushing the excised
uterus with sterile Dulbecco's phosphate buffered saline (DPBS; Dulbecco
and Vogt, 1954) containing 10 m1/1 of an antibiotic-antimycotic solution
(10,000 units penicillin, 10 mg streptomycin and 25 gg amphotericin B per
mlin 0.9% sodium chloride; Sigma) and either 1% heat-treated bovine
serum or 0.5% BSA (Sigma).Uterine flushings were examined with a
dissecting microscope and blastocysts were recovered from the flushings
byaspirationwithsterileglass micropipettes or Pasteurpipettes
(Figure 6).Recovered blastocystswere washed in5ml of Ham's F-1234
Figure 6.Hatched bovine blastocyst recovered 13 d after onset of estrus
(X 390).35
(Sigma) containing 15 mg/ml BSA and assigned to either Experiment I or
II.
In Experiment I, 12-14 d blastocysts were cultured for 24 h in 100
pl microdrops of Ham's F-12 containing 15 mg/ml BSA under paraffin oil
(Fisher Scientific Co., Tustin, CA) in a humidified atmosphere of 5% CO2
in air at 37°C (Figure 7).At initiation and end of culture, blastocysts
were observed for morphology and photographed using an inverted stage-
phase contrast microscope at 40-200X.Following culture, embryos and
medium were recovered separately from the culture drops by aspiration,
placedinto 1mlsnap-capvials,andfrozenat-20°Cuntil
electrophoresisandzymography. Todetectanycontaminationof
plasminogen, PA or plasmin in the culture medium, medium without embryos
was incubated under identical conditions and assayed similarly as other
medium samples.In Experiment II, blastocysts were either microdissected
into component embryonic discs and trophoblast or not dissected (Figure
8).Microdissection was conducted using a microscalpel and microforceps
while visualizingthe embryoat70X withadissecting microscope.
Embryonic discs, trophoblast and intact embryos were cultured for 24 h,
photographed,andtissues,and media were recoveredandstoredas
described in Experiment I(Figure 9).36
Figure 7.Petridish containing14dbovine blastocystsin100 yl
culture drops (1-3).Culture drop 4 contains medium without
embryos (X 1.8).37
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Figure8.Dissected embryonic disc (a,X 360)and trophoblast(b,X
72) from 14 d bovine blastocysts prior to culture.Arrow
indicates site from which embryonic disc was dissected.38
Figure 9.Embryonicdiscsdissectedfrom14dbovineblastocysts
cultured for 24 h(X 360).39
Sample Preparation, Electrophoresis and Zvmographv (see APPENDIX A for
further details).
Inboth experiments theProtean DualSlab Cellelectrophoresis
apparatus(Bio-RadLaboratories,Richmond,CA) wasusedfor one-
dimensionalSDS-PAGE under non-reducing conditions withamodified
casein-agar gel underlay technique known as zymography (Granelli-Piperno
and Reich, 1978; Vassalli et al., 1984).Embryonic tissues were thawed,
homogenized by repeated aspiration with a micropipette and combined with
equivalent volumes of 2X sample buffer (5.0% SDS; 20% glycerol; 0.0025%
bromophenol blue in 0.125 M Tris-HC1 buffer) or at least 30 Al of 1X
sample buffer if the amount of tissue was small, as was the case with the
embryonic discs.Media samples were combined with an equal volume of 2X
sample buffer.Urokinase (E.C. 3.4.21.7) standards (Sigma) were prepared
with 1X sample buffer to final concentrations of 1.0, 0.5, and 0.1 milli-
Units/ml. Tissue-PA standards(Sigma)usedinExperimentIIwere
prepared with 1X sample buffer to final concentrations of 1.0 and 0.5
Ag/ml.Each 160 X 135 X 1.5-mm thick electrophoretic slab gel included
one lane containing the following MW markers (Bio-Rad): phosphorylase b
(97.4 kD), bovine serum albumin (66.2 kD), ovalbumin (42.7 kD), carbonic
anhydrase (31.0 kD), soybean trypsin inhibitor (21.5 kD) and lysozyme
(14.4 kD).The MW markers were prepared by combining a stock concentrate
with 1X sample buffer in a 1:10 ratio.Urokinase and tPA standards as
well as MW markers were routinely tested by zymography for activity prior
to co-electrophoresis with embryonic tissue and media samples.Samples
and standards were vortexed to ensure complete mixing with applied40
buffers.Urokinase, tPA and MW markers were aliquoted in 100 Al volumes
into castellated wells in a 4.0% acrylamide stacking gel with a 12.0%
separating gel.Prepared blastocyst tissue and media were aliquoted onto
the acrylamide gels in 30-100 Al volumes. Electrophoresis was conducted
under constant voltage at a current of 15 mA/gel through the stacking gel
and 30 mA/gel through the separating gel for 2 to 4 h until the dye front
reached the bottom edge of the separating gel.
Following electrophoresis, the Protean Dual Slab Cell apparatus was
disassembled and the slab gels were gently agitated in 2.5% Triton X-100
(Sigma) for 30 min, rinsed with distilled water 3 times and incubated in
DPBS for 30 min.The gel was carefully placed on plastic wrap, excess
DPBS blotted gently with tissue paper, and a casein-agar gel containing
purified human plasminogen (Sigma) supported on a glass plate was applied
to the surface of the polyacrylamide slab gel.The casein-agar gel
plates were prepared by dissolving 2 g of nonfat dry milk (Carnation Co.,
Los Angeles, CA) in 100 ml of buffer containing 0.0013 MCaC12 2H20, 0.10
M glycine, 0.038 M Tris and 0.005 M Na azide.Twelve milliliters of the
nonfat dry milk were heated to 55°C and combined with 12.0 mlof 2%
melted agarose (Sigma) also maintained at 55°C.Purified human plas-
minogen was added to the warmed mixture in sufficient volume to yield a
final concentration of 2C-25 µg /ml.The total volume of this mixture was
then cast onto a warmed :3.5 x 16.0 cm glass plate and allowed to cool.
In ExperimentI,electrophoretic gels were run in duplicate so as to
apply one casein-agar gel plate containing human plasminogen and the
other plate containing no plasminogen.Plasminogen activators, including41
urokinase and tPA, which diffused frog the electrophoresed slab gels,
would show lytic zones in casein-agar gels containing 20-25 µg /ml human
plasminogen.The casein-agar gel plate containing no plasminogen and
incubated with electrophoretic gels served as a control to detect non-
specific proteases.Gel "sandwiches" were incubated at room temperature
for 24-48 h and observed for lysis hourly for several hours, and every
4h thereafter.Protease migration was measured during incubation by
measuring, to the nearest millimeter, the distance from the edge of the
separating gel to the center of clear lytic bands in each lane. Gel
incubation was terminated by separating the gelsandwich, fixing the
casein-agar plate with 3% acetic acid for 10 min, and rinsing under tap
water.Casein-agar gelplates were dried and stained for permanent
storage.Electrophoresed slab gels were stained with 0.05% Coomassie
Brilliant Blue (Bio-Rad) in 65/25/10 water/isopropanol/acetic acid for
4-8 h and destained in 80/10/10 water/isopropanol/acetic acid overnight.
After destaining electrophoretic polyacrylamide slab gels were dried for
permanent storage with a Hoefer Scientific SE-540 Slab Gel Dryer.
Each caseinolytic zone in lanes containing PA from culture medium,
blastocyst tissues,or urokinase standards served as an observation.
Relative mobilities (Rm) of urokinase standards and bovine blastocyst
PA were calculated by dividing the distance of migration from the point
of origin on the separating gel to the center of the casein-agar lytic
zone by the total length of the slab gel.Molecular weights of PA were
determined by log MW-Rm plots derived from the MW markers.Correlation-
regression calculationsprovided theequation of thelineandthe42
correlation coefficients for the log MW-Rm plots (Steel and Torrie, 1980;
Sincich, 1985).UnknownMW were calculated from the equation of the
line.Differences among MW of PA secreted into the culture medium or
contained in blastocyst tissue were detected using the unpaired t-test.Results
Embryo Collection
43
A total of 111 embryos of normal morphology were collected from 11
of the 22 cows for a recovery rate of 10.1 embryos per cow.Unfertilized
ova or degenerate embryos were collected from two cows and neither ova
nor embryos were recovered from the remaining 9 cows.
SDS-PAGE and Zvmography
The mean correlation coefficient for plots of log MW by Rm used to
calculate the MW of urokinase and tPA standards and embryonic PA was-
.99 ± .01 for 27 SDS-PAGE runs.Molecular weights of urokinase standards
co-electrophoresed with embryonic tissues and media were 57.5 ± 0.6 and
38.2 ± 0.5 kD for the high and low MW forms, respectively (Table 1).
Because no difference(P>.05)was detectedinMW of highandlow
urokinase forms between Experiment I and II, the data reported in Table
1 are means pooled from the two experiments.The tPA used as a standard
in Experiment II exhibited a MW of 63.6 ± 0.5 kD.
In Experiment I, 12-14 d bovine blastocysts contained and secreted
both an uPA and a tPA (Table 2, Figure 10).No difference was seen in
MW of uPA between undissected blastocyst tissue and the respective
culture medium (P>.05).The MW of tPA observed in the medium was greater
than that observed for tPA in blastocyst tissue (P<.05); however, the
number of observations for the tPA MW determination was low.44
The MW of uPA and tPA in medium and tissue from intact blastocysts
and trophoblast in Experiment IIare reported in Table 3.Molecular
weights of uPA and tPA did not differ due to source of tissue (P>.05).
Plasminogen activators were not detected in either embryonic disc tissue
or its respective culture medium (Figure 11).TABLE 1. MOLECULAR WEIGHTS(kD)OF
ACTIVATOR (PA) STANDARDS
UROKINASE AND
45
TISSUEPLASMINOGEN
Standard n Molecular Weight'
Urokinase
High molecular weight form
Low molecular weight form
Tissue PA
52
48
19
57.5 ± 0.6
38.2 ± 0.5
63.6 ± 0.5
'Mean ± standard error of the mean.46
TABLE 2. MOLECULAR WEIGHTS (kD) OF PLASMINOGEN ACTIVATORS PRODUCED BY
BOVINE BLASTOCYSTS
Source n Molecular Weight' nMolecular Weight
Blastocysts 5 48.0± 1.1b 2 84.5± 0.3b
Medium 7 46.3± 1.6b 3 87.3± 0.4b
Blastocysts and
medium 12 47.0± 1.0 5 86.1± 0.7
'Mean ± standard error of the mean.
b'Values in the same column without common superscripts are different
(P<.05).47
TABLE 3. MOLECULAR WEIGHTS (kD) OF PLASMINOGEN ACTIVATORS (PA) PRODUCED
BY INTACT BLASTOCYSTS AND DISSECTED TROPHOBLAST IN THE BOVINE
Source n
Urokinase-type PA Tissue-type PA
Molecular Weights nMolecular Weight
Intact blastocysts 15 42.5 ± 1.8 4 91.4± 4.0
Trophoblast 10 40.0 ± 2.6 3 93.2± 4.2
Intact blastocysts
and trophoblast 25 41.5 ± 1.5 7 92.2± 2.7
aValues reported are means ± standard error of the mean of MW for PA
determined from tissue and media samples.mik
1 2 kD
- -97
1111,-66
1116-45
lamb 31
22
Mk 14
48
Figure 10.Caseinolytic zymograph of cultured 12-14 d bovine blastocysts
(lane 1) and polyacrylamide gel containing MW markers (lane
2).Arrows point to lytic zones caused by embryonic tPA (A)
and uPA (B).Molecular weight markers in order of descending
MW are:phosphorylase b, bovine serum albumin, ovalbumin,
carbonic anhydrase, soybean trypsin inhibitor, and lysozyme.49
Figure 11.Zymograph of microdissected 12-14 d bovine blastocysts and
urokinase standards.Lane 1,intact embryo; Lane 2 and 4,
culture medium without embryos; Lane 3, trophoblast; Lane 5,
embryonicdisc;Lane6,nosample;Lane7,0.1mU /ml
urokinase; and Lane 8, 0.5 mU/m1 urokinase.50
Discussion
Zymographic analysis for PA revealed that 12-14 d bovine blastocysts
contain and secrete both an uPA (41.547.0 kD) and a tPA (86.1 92.2
kD).Molecular weights of urokinase standards observed in the present
study were similar to values reported by Christman et al. (1977) for the
high (54.7 kD) and low (31.4 kD) MW forms of the protease.The MW of the
tPA used as a standard in Experiment II also agrees closely with the 60
kD value reported by Christman et al. (1977) for tPA produced by cultured
human melanoma cells.Accuracy of the MW determination for PA may vary
accordingly with the precision of Rm measurements, especially with the
higher MW proteases (i.e.,tPA). SmallRm variations can result in
substantial variations in MW calculation, perhaps by as much as several
kD.Such variation in Rm measurements may account for the differences
in MW observed between Experiments I and II for uPA (47.0 vs. 41.5 kD)
and tPA (86.1 vs. 92.2 kD).Likewise, it is improbable that the MW for
the tPA in blastocysts and media reported in Table 2 are biologically
distinct.
The incidence of detection of the embryonic uPA was approximately
threefold greater than that for the tPA.This suggests the embryonic
tPA is either more labile than the uPA or not as readily expressed.The
latterisindeedpossible because tPA anduPAareimmunologically
distinct and produced by different genes (Dano et al., 1985; Degen et
al., 1986).In the present study, embryonic PA activity was associated
only with the trophoblast; however, the amount of embryonic disc tissue
was considerably less compared to the intact blastocysts and dissected51
trophoblast. Itispossible that PA activity associated with the
embryonicdiscwasnotdetected. Sensitivityofthezymographic
technique can be adjusted by varying the plasminogen concentration in
casein-agar overlays and the incubation time of gel sandwiches (Granelli-
Piperno and Reich, 1978).Nevertheless, trophoblastic production of PA
accounted for the principal source of embryonic PA.
Dormant tPA mRNA has been identified in mouse oocytes and tPA is
synthesized by mouse oocytes undergoing meiotic maturation (Huarte et
al., 1987).Mouse embryonic PA disappears shortly after fertilization
(Huarte et al.,1985) and reappears at the time of implantation and
subsequent developmental events (Sherman et al.,1976; Strickland et
al., 1976). In the cow, Menino and Williams (1987) have suggested a
time-dependent mechanism is in effect regulating embryonic PA production
because PA is not produced in significant quantity until the expanded
blastocyst stage.Although the physiologic significance of PA to early
embryodevelopmentisnotknown,MeninoandWilliams(1987)have
suggested that plasminogen activation to plasmin by the blastocyst may
be a mechanism utilized by the embryo to effect a sublysis of thezona
pellucida and thereby facilitate hatching.Besides a potential role in
hatching, PA may also be involved in the series of morphologic changes
occurring in bovine embryos between Days 8 to 16.Embryonic endoderm
migrates beneath the trophectoderm starting on Day 8 to form trophoblast
and on Day 12 the embryonic disc ruptures through the trophectoderm
(Betteridge and Flechon, 1988).Mesodermal cells from the embryonic disc
also begin to migrate between the trophectoderm and endoderm on Day 14
(Betteridge and Flechon, 1988).Contingent with these cell migrations,52
the shape of the hatched blastocyst then changes from spherical to ovoid
duringatransitory phase preceding elongation thatusually begins
between Days 12-14 (Betteridge and Flechon, 1988).Marotti et al. (1982)
observed that mouse endoderm produced a tPA and visceral endoderm and
extraembryonic mesoderm an uPA and speculated a role for PA in cell
migration during mouse embryogenesis.Results of the present study
suggest 12-14 d bovine blastocysts produce both uPA and tPA, and the
possibility of a modelin the bovine similar to the mouse, where both
types of PA are involved in tissue remodelling and blastocyst elongation.53
Conclusion
One goal of researchers in embryo physiology is to link parameters
of embryo biochemistry, such as PA production, to applicable reproductive
technologies.Embryo transfer has been successfully performed in many
mammalian species; however, most research and commercial application of
thistechnologyinlivestockappearstobedocumentedincattle
(Betteridge, 1977).As biotechnology advances, research in bovine embryo
physiologywillcontinuetofocusonmicromanipulation,invitro
fertilization,nucleartransplantation,cryopreservation,sexing,
cloning, and immunology.
Plasminogen activator production may have potential as an indicator
of bovine embryo viability prior to transfer and success in pregnancy
establishment (Kaaekuahiwi and Menino, 1989). Molecular characterization
and aspects of bovine embryonic PA may provide information as to how this
biomolecular system functions in vivo and the significance of it during
early development.54
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I.Solutions, Chemicals and Samples
A.10% ammonium persulfate solution (must be fresh every 36 h).
0.05 g ammonium persulfate to 500 gl of distilled water.
Dissolve in a snap-cap vial and store in refrigerator until
needed.
B.10% (w/v) SDS Solution:
Dissolve 10 g of SDS into 100 ml of dH2O.Can be stored on lab
shelf.
C."Stock" solutions, as described in Bio-Rad Protean Dual Slab
Cell Operating Instructions (Appendix, pp. 31-32):
1.Acrylamide:BIS (30% T, 2.67% C)
29.2 g acrylamide (Note:acrylamide is a neurotoxin and
should be handled with utmost care.Use gloves/mask when
handling.)
0.8 g N'N'-BIS methylene acrylamide
q.s. 100 ml with dH2O (i.e. "bring to volume")
Call this "Solution A".No need to filter. Store in
dark bottle in refrigerator (30 d maximum).
2.1.5 M Tris-C1, pH 8.8
18.15 g Tris base
50 ml dH2O
Carefully adjust to pH 8.8 with 1N or conc. HC1.
q.s. 100 ml with dH2O.
Call this "Solution B" and store in refrigerator.
3.0.5 M Tris-C1, pH 6.8
3.0 g Tris base
35 ml dH2O
Carefully adjust to pH 6.8 with 1 N or conc. HC1. Then
q.s. to50 ml with dH2O.
Call this "Solution C" and store in refrigerator.
D.Electrode Buffer:Four liters is made up for each gel run.
According to Bio-Rad instructions (p. 33), make up 4 1by first
adding 12.0 g Tris base and 57.6 g Glycine to approximately 21
of dH2O.Stir while mixing.Then add 4.0 g of SDS slowly as a
powder.Avoid frothing.q.s. to 41with dH2O.62
E.Sample Buffer:per Bio-Rad directions (p. 33):
4.0 ml dH2O
1.0 ml 0.5 M Tris-C1, pH 6.8 ("Solution C")
0.8 ml Glycerol
2.0 ml 10% (w/v) SDS
0.2 ml 0.05% (w/v) Bromophenol Blue (Aqueous Solution)
8.0 ml TOTAL.Multiply all components by 2 for 16.0 ml
Multiply all components by 2 (except dH2O) for 2x
sample buffer
Store in bottle on shelf.Note that no 2-mercaptoethanol for
PA zymographic analysis is used with this technique.
F.Standard and Sample Preparation
1.Urokinase (E.C. 3.4.21.7) Standards (Sigma, No. U-6876):A
serial dilution is normally used in which a frozen stock
solution of 0.2 units/ml = 200 mU /ml Urokinase is diluted.
Example:
Cstock
(mU /ml)
VO1stock
(Al)
Voldii (µl )
(Sample buffer)
Cfinal
(mU /ml)
Volfinal
(ml)
200 50 1,950 5.0 2.0
5.0 200 800 1.0 1.0
5.0 100 900 0.5 1.0
5.0 20 980 0.1 1.0
0.5 100 900 0.05 1.0
0.1 100 900 0.01 1.0
0.5 10 990 0.005 1.0
0.1 10 990 0.001 1.0
Volumes are to be combined accordingly into fresh tissue
culture tubes and can be stored on lab counter.
2.SDS-PAGE Low Range Molecular Weight Standards (Bio-Rad,
#161-0304).
Standards are diluted 1:10 by combining 50 Al of stock
concentrate from frozen snap-cap vial to 450 Al of Sample
Buffer.1 Al of Phenol Red can be added as a color dye
indicator.
Heat for 3-5 min at 95°C.Prepared Standards can be loaded
onto full-length gel wells (50 Al minimum) and can be
stored on lab counter.63
3.Tissue-type Plasminogen Activator (tPA) stock solutions
(Sigma, No. T-7776).Use serial dilution from 10 µg /ml
stock solution.
Cstcnk Volstock Voldii(p1) Cfinal Volf
(µg /ml) (p1) (Sample Buffer) (µg /ml) (ml)
10.0 60 540 1.0 0.6
1.0 200 200 0.5 0.4
1.0 50 450 0.1 0.5
Volumes are combined accordingly into separate tissue
culture tubes and can be stored on lab counter.
4. Human Plasminogen (hPgn) stock solution at 1200 gg/m1=1.2
mg/ml (Sigma, No. P-5661).
Normally recieved in solid form and must be diluted with
sterile DPBS to 1.2 mg protein/ml.
Example:New Vial = 25 Units
84 mg solid
0.32 Units/m1 solid
6.0Units/m1 protein
25 units x
1.0 MCI protein
- 4.167 mg protein
6.0 units
1.2 mg 4.167 mg
1 ml = x ml x=3.47 ml
4.167 mg protein is thoroughly dissolved into 3.47 ml of
sterile) DPBS, then dispensed into snap cap vials.hPgn
should be aliquoted into various volumes before freezer
storage.
5.Embryo Tissue and Media Samples
a.Tissue samples are homogenized with a micropestle or
via aspiration in and out of a micropipet tip, then
combined in a 1:1 ratio with lx or 2x Sample Buffer.
b.Media samples are measured for volume and combined 1:1
with Sample Buffer.
The highest sample volumes possible should be drawn up in
order to complete electrophoresis and allow for maximum PA
detection on a caseinolytic agar gel plate "sandwich".64
G.Phosphate Buffered Saline (DPBS)* (Dullbeccos and Vogt, 1954,
J. Exp.
1.
2.
3.
4.
5.
Med. 99:167-82).
For 1.0 liter For 41DPBS:
8.00 g NaC1
0.20 g KC1
1.15 g Na2HPO4
0.20 g KN2PO4
0.10 g MgC12 6N20
32.0 g
0.8 g
4.6 g
0.8 g
0.4 g
Rinse out each tray as you add to the flask, and bring to
volume to 700 ml.
6.Make up CaC12 (0.10 g) separate to 100 ml with dH2O.Then
slowly add this to the 700 ml volume (0.40 g CaC12 to 400
ml dH2O for 4.0 1PBS).
q.s. to total volume of 1000 ml with dH2O.q.s. to 4000 ml
for 4 1.
7.Store chilled, or conveniently on lab counter.No
antibiotics are added for zymography.
H.Triton X-100 (2.5%)* (Sigma or Bio-Rad):
Make up 21of this solution by mixing 50 ml of Triton X-100
reagent with 1,950 ml dH2O.
*Note: DPBS and Triton X-100 solutions are to be used later
whenrinsing the gel prior to caseinolytic agar plate
application.
I.Stains and Destaining Solutions (for use after Section VIII)
1.Coomassie Brilliant Blue (CBB) R-250 (Bio-Rad):
0.05% in 65/25/10, water/isopropanol/acetic acid (can even
be reused after filtering):
1.0 g CBB R-250 dissolved in:
1300 ml dH2O
500 ml isopropanol
200 ml acetic acid
2000 ml(2 1)TOTAL
2.CBB Destaining Solution:65
(80/10/10, water/isopropanol/acetic acetic)(Can also be
reused if fairly clear.)
3200 ml dH2O
400 ml isopropanol
400 ml acetic acid
4000 ml(4 1)TOTAL
3.Amido Black Stain, 0.1%:
1.0 g Amido Black q.s. to 200 ml dH2O
100 ml acetic acid
700 ml methanol
1000 ml(1 1)TOTAL
4.Amido Black Destaining Solution:
700 ml methanol
100 ml acetic acid
200 ml dH2O
1000 ml(1.0 1)TOTAL
II. Casting a 13 x 10 cm caseinolytic agar gel plate containing 20-25
µg /ml hPgn.This can be done at any time during the course of
running an electrophoretic gel.However, it is best to do this
after section VII. B., but before section VIII.The following
protocol is a common example.
A.7.375 ml skim milk with azide "stock" mixture
7.375 ml 2% "stock" agarose solution
250pl hPgn (1.2 mg/ml)
15.0 ml TOTAL volume enough to cover a 10 x 13 cm glass
plate.
B.Follow the standard protocol for caseinolytic assay agar gel
plate preparation.
1.Buffer preparation:
CaC12
glycine
TRIS
NaAzide
2H20
Molarity IA/1
.0013
.10
.038
.005
.195
7.51
4.6
.32566
2.Dissolve 2 g of nonfat dry milk (Carnation) in 100 ml of
buffer (2%).The azide preserves the milk.
3.Dissolve 2 g of agarose (Sigma) in 100 ml of dH20 (2%).
Then autoclave for 30 min to 100°C.
4.These skim milk and agarose mixtures must be made up fresh
for each caseinolytic assay.
C.Example:For Plasminogen Activator activity detection, combine
equal (1:1) volumes of the heated stock mixtures.
10 ml skim milk
10 ml 2% agarose
20 ml of 1:1 solution at 60°C
D. Take 14.75 ml of above mixture and cool to approximately 55°C
in a separate beaker.
E.Immediately add 250 Al of the hPgn, and mix thoroughly.Total
volume is now 15.0 ml.
F.Quickly draw up into a pipet and cast onto a warmed 13 x 10 cm
glass plate.It is important to do this quickly and evenly in
order to get a uniform plate.Then put the cast plate under a
cover until later use (i.e., after section VIII).
NOTE: One can always increase or decrease the total volume
and hPgn concentrations to meet desired sensitivity
specifications for the zymographic assay.
III. Assembly of Protean Dual Slab Cell:(Also in Bio-Rad
instructions, pp. 1-33.)
Make sure all plastic equipment and glass plates to be used are
very clean and/or tissue-culture (TC) washed..75 mm or 1.5 mm
gels can be made.The casts are to be set before making the gel
mixtures.
A. Lay down two 18 x 16 cm glass plates on a clean lab
counter.On one, place two "spacers" (grey strips) on each
16 cm edge.Lay the other glass plate on and match up the
edges.Keep surfaces clean!Avoid fingerprints!
B. Attach sandwich clamps with one screw slightly tightened on
each side (Fig. 1, p. 13).
C. Line up spacers, glass plates, and sandwich clamps
squarely.This is very important because the cast may leak
if it is not fit together tightly and squarely.Then67
uniformly tighten all sandwich clamp screws.(Note:Avoid
using metal spatulas to adjust the spacers between the
plates and sandwich clamps because the plates chip easily.)
D. Insert the assembled glass plates, spacers and sandwich
clamps into the casting stand as shown in Fig. 2 on p. 13.
Place a 3 cm wide strip of parafilm between the latex
rubber gasket and the bottom edge of the glass plate
assembly.In case of any leakage, this parafilm can be
stretched to aid in sustaining the leak.Tighten down the
assembly using "locking cams" (as in Fig. 3, p. 13).One
can also cast a "base seal" onto the parafilm described in
section IV.
E.Before making the gels, insert the correct size plastic tubing
and needle in between the sandwiched glass plate assembly.
Have all equipment and syringes ready for casting the gels,
since it gelates rather quickly.
IV. Casting Gels
A. A "gel seal" cast at the base of the assembled glass plates is
optional, but highly recommended, since the plates sometimes
leak regardless of what is done.
1.For a total of 5.0 ml:
1.675 ml dH2O
1.25ml solution "B"
50 Al SDS
2.0ml solution "A"
25 Al ammonium persulfate
2.5Al TEMED (N, N, N', N',-Tetramethyl-ethylendiamine)
5.0 mlTOTAL
2.Cast onto the parafilm at the base of the glass plates and
allow to gelate in order to seal any chips or cracks.
B.Separating gel preparation:
1.A 12% acrylamide gel has been routinely used with good
resolution.(See Bio-Rad instructions, p. 32).68
2.A 1.5 mm separating gel is most sturdy for handling.The
formula for one 1.5 mm gel (or two .75 mm gels) is as
follows:
13.4ml dH20.
10.0ml 1.5 Tris-C1, pH 8.8 ("Solution B")
0.40 ml(400 Al) 10% (w/v) SDS
16.0ml acrylamide:BIS (30% T, 2.67% C) ("Solution A")
*0.2ml (200 Al) 10% ammonium persulfate
(fresh 36 hours)
*0.02 ml(20 Al) TEMED
40.02 ml TOTAL
*NOTE: The ammonium persulfate and TEMED are to be added
last as catalysts.Swirl gently.
3.With 14 gauge blunt needle on a 30 cc syringe, aspirate the
gel mixture.Quickly switch to the 18 gauge needle and
tubing already inserted between the sandwiched glass
plates.Steadily and evenly drain the gel into the
assembly.
4.Fill the assembly up to the level of the inserted solid
spacer (approximately 35-40 mm below the top edge of the
glass plate assembly).Be sure to rinse all syringes,
needles and tubes immediately after use.
5.Let set for 1 min before dripping on a layer of distilled
water.Then allow the separating gel to harden for at
least 1 hour.
C.Stacking gel preparation:(refer to Bio-Rad instructions
p. 32).
1.After the separating gel has set, carefully drain off the
layer of dH2O.
2.Insert a white 1.5 mm 10-well comb between the sandwiched
plates above the separating gel.Each sample well can
normally contain up to 125 Al of sample.
3.Insert the 1.5 mm tubing between the plates again and have
30 cc syringe with 14 gauge blunt needle ready before
mixing stacking gel.69
4.The formula for one 1.5 mm 4.0% acrylamide stock gel(or
two .75 mm gels) is as follows:
6.1 ml dH2O
2.5ml 0.5 M Tris-C1, pH 6.8 ("Solution C")
0.10ml (100 Al) 10% (w/v) SDS
1.3ml acrylamide:BIS (30% T, 2.67% C) ("Solution A")
*0.05ml(50 Al) 10% ammonium persulfate (fresh)
*0.01ml(10 Al) TEMED
10.06ml
*Ammonium persulfate and TEMED to be added last as catalysts.
5.Swirl gently, then quickly aspirate the stacking gel
mixture into the 30 cc syringe and switch to the 18 gauge
needle with attached tubing.
6.Begin casting by providing an even and constant pressure,
and fill up plates to combs until about 1 mm from the top
edge.
7.Allow to set for 5 min before applying distilled water.
Carefully drip the dH2O on, then let stacking gel set for
at least 0.5 hr to insure complete gelation.
8.After gelation, the comb can be removed very carefully (in
order to avoid collapsing the formed wells).
9.Rinse the wells 2x with electrode buffer using syringe and
20 gauge needle.Then fill wells with electrode buffer.
The sandwich plates and gels are now ready to be attached
to the upper buffer chamber and inserted into the lower
buffer chamber.
V. Assembly of electrophoretic apparatus (refer to Bio-Rad
directions and diagrams, pp. 13-14):
A.After the wells have been rinsed and filled with electrode
buffer, attach the upper buffer chamber with latex rubber
gaskets in place to the glass plate asssembly and the
buffer dam or "dummy" slab cell (if only 1 gel is being
run).Tighten with locking cams (Fig. 3, p. 13).
B.Remove the assembly from the casting stand, latex rubber
gasket, and parafilm.
C.With the "exchange cooling system" in place in the lower
buffer chamber and attached to a tap water faucet draining
into the sink, fill the lower buffer chamber with electrode70
buffer to approximately 2 1.Make sure the lower buffer
chamber sits as level as possible on the stir plate with
stir bar in it.
D.Insert the entire assembly of upper buffer chamber, glass
plates, sandwich clamps, and cast gels into the lower
buffer chamber.(See Fig. 5,p. 14).
VI.Once the apparatus is set up as in Fig. 6, p. 14, the samples can
be aliquoted to their respective wells on the stacking gel.It
has been recommended not to use wells 1 and 10 due to poorer
resolution in those wells.
A.List on a standard gel electrophoresis data sheet the
samples to be put into each well along with respective
sample volumes.
Example:Run an "embryo sample" in well 2; 0.05 mU /ml
Urokinase standard in well 6; 0.1 mU/m1 Urokinase
standard in well 7; and SDS protein standards in well
9.
It is recommended to skip wells among samples in order to
prevent contamination during aliquoting.
B.Procedure for homogenized embryo tissue or media samples.
(Consult Dr. Menino.)
Frozen embryo samples should be thawed first.Use a
micropestle in a microcentrifuge tube to homogenize any
tissue samples, and combine with the proper ration of lx or
2x sample buffer.Tissue can also be homogenized by
aspiration in and out of a micropipette tip.
C.Aliquot standards and samples using a micropipette (P-100)
and long flat Multip-Flex pipet tips.Normally,
approximately 100 Al of sample can be aliquoted to each
well without complications.Avoid bubbling!
D.Once samples have been aliquoted, slowly pour electrode
buffer into the upper buffer chamber up to the level of the
angled seams.The gel is now ready to run.
VII.Running a polyacrylamide gel.
A.Put the plastic cap with electrodes that is hooked up to
the power supply onto the assembled gel apparatus.
B.With voltage button (top) at 500 V and current button at 20
mA (bottom), turn on the power supply.The voltage knob is
to be turned clockwise all the way, and adjust the current
knob to read 15 mA per, gel.Note the time of start-up.71
Also refer to Bio-Rad Model 500/200 Power Supply
instruction manual.Note safety procedures.
C.Occasionally adjust the current knob back to 15 mA, and
check the apparatus to see that it stays cooled during
electrophoresis.
D.As soon as the sample tracker dye front has gone from the
stacking gel to the separating gel, switch the current
button up to 200 mA and adjust to 30 mA per gel.
It normally takes 1-2 h for the dye to run through the stacking
gel.The gel will then run for approximately 2-4 h.Check to
insure the system is cool and running at 30 mA per gel.
Now, in the meantime, one could cast a caseinolytic agar gel
plate.Refer to Section II.
E.Towards the end of 3-4 h, the tracker dye front will
approach the bottom edge of the separating gel.Shut the
power supply off when it has reached the bottom edge of the
separating gel.
Have the caseinolytic agar gel plate ready by this time.
VIII. Processing the Electrophoresed Gel
A.Disassemble the protean dual slab cell and electrophoresis
apparatus, and put the used components in a clean tap-water
rinse tub for the time being.TC wash later.
B.When separating the glass plates from the gel, be as
careful as possible so as not to rip or break the gel
itself.Note where the lanes are according to the stacking
gel portion, and make notches in the separating gel in
order to note orientation for later reference.
C.(Optional)The protein standard lanes can be separated
first off by a scalpel blade, and then put into CBB-R250
stain for a minimum of 4 h.This portion of the gel is
then put into CBB Destainer solution for several h.
Occasionally change the destaining solution.Remember its
orientation!Note this aspect of the protocol is optional.
We do not do this routinely.
D.Procedures for the Urokinase Standard and Embryo Sample
lanes.Handle the gel with care and use gloves.
1. Put the gel into a plastic rinse box containing
Triton X-100 for 20-30 min on the shaker.Continue
to note orientation.72
2. Then run it through a dH2O rinse 3X.
3. Put into DPBS solution in a plastic rinse box for
20-30 min.
4. Remove the gel from the DPBS onto a clean piece of
plastic Saran wrap large enough to completely wrap
the gel.
5. Carefully blot the gel dry with tissue paper in order
to rid any excess DPBS and moisture.
6. Place the 10 x 13 cm caseinolytic agar plate onto the
gel, lining up the top edge of the gel with the top
edge of the glass plate.Even though urokinase lanes
are normally separated from the embryo sample lanes
by several centimeters, the plates can be
conveniently placed so as to include both urokinase
and embryonic plasminogen activator detection.
E.The acrylamide-caseinolytic gel "sandwich" is now ready for
incubation. Wrap this "sandwich" in the plastic wrap and
place on the lab counter to incubate at room temperature.
1. The plate is to be checked every h and observed for
any lysis.
2. The urokinase standards may show lysis only after 1-2
h of incubation, depending on the concentrations
used.Make measurements from the edge of origin to
the most accurate assessment of the center of the
lytic band.
3. The embryo sample lane may take from 1 to 36 h to
show any lysis.(Refer to article by
Grannelli-Piperno and Reich, J. Exp. Med. 48:223-24).
4. During incubation and detection of lysis, measure and
record distances from the plate's edge to the center
of the bands.These measurements are important in
calculations and log-MW plots.
F. After incubation, the acrylamide portion of the gel
sandwich can be put into CBB R-250 stain and
subsequent destainer.Note that it takes longer for
the caseinolytic section of the gel to destain than
the other part.4 h CBB, 1-2 d in destainer.
G. After incubation, the caseinolytic agar gel is fixed
with 3% acetic acid for 10 min, then carefully rinsed
with tap water.73
H. Follow up this work with additional measurements,
calculations, and log MW plots.
IX.Measurements, Calculations, Log-MW Plots, and Scanning
Densitometer Use.
A.Measurements during and after gel "sandwich" incubation.
1. Realizing the correct orientation of the gels and sample
lanes, measure the distance (in mm) from the origin edge of
the glass plate to the center of each lytic band.
These measurements should be done as soon as the lytic
bands are distinctly visible in each lane (approx. 1-2 h of
incubation).
2.Calculate Relative Mobilities (Rm) simply by dividing the
distance to the center of the lytic band by the total
length of the gel.
distance to lytic band center
Rm =
total gel length
3.Rm's can also be measured and calculated for the SDS and
BSA Protein Standard Lanes after they have been processed
and are ready for use on the Scanning Densitometer
(optional).A standard curve should also be calculated.
a.Set up the following table for the SDS Protein
Standards.
Protein
Phosphorylase b
BSA
Ovalbumin
Carbonic anhydrase
Soybean trypsin
inhibitor
lysozyme
b.Then calculate:
MW log MW (X)Rm (Y)X'Y
97,400 4.989
66,200 4.821
42,699 4.630
31,000 4.491
21,500
14,400
4.332
4.158
EX=27.422 EY= EXY=
EX2= 125.801 EY2=
X=4.570c.Finally, follow standard statistical procedures for
simple linear regression and correlation using
Y= a + bX
where:Y = Rm
X = log MW
a = y-intercept = Y bX
b = slope of the line = SSxv
SSxx
and
SSxx = Exy
SSxx = Ex2
SSyy = Ey2 -
n
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and:
r = ,the correlation coefficient
J'SS SSyy
The slope (b) should be negative, and r should be close to 1.000
d.Now, substitute in the Y (Rm) values from unknown MW
species, to calculate X (log MW) and essentially MW.
Example:For Urokinase (with 2 chains showing 2 different
lytic bands):
V1 a
(log MW1) X1 =
b
Antilog --> MW1
where Y1 is that band's Rm, a is the calculated
y-intercept, and b is the calculated slope of
the standard curve.Also,X2 =
Y2 a
b
75
Antilog --> MW2
(Standard Statistical Procedures taken from Sincich T, 1985.
Statistics by Example, Second Edition.San Francisco:Dallen
Publishing Co.)
B.Log MW Plots and Scanning Densitometer (optional).Refer
to the IBM version of the GS-350 Data System and the
Bio-Rad manual for the Model 1650 Transmittance/Reflectance
Densitometer Operating Instructions.
X. Photographing gels with the Polaroid MP-4 Land Camera (refer to
instruction manual, also) or your own 35 mm camera.
A.The gel is placed on the white fluorescent lamp table under
the camera; or using extraneous light sources in the
darkroom.
B.Remove lens cap.
C.Adjust with up and down knobs for image focusing.
D.Set Lens Aperture (lower knob) and Shutter Speed (upper
knob).These can be adjusted as to desired specifications
for conditons pending.
E.Slide the vision box over and remove the lens cap before
photographing.
F."Click" the shutter release on the lens, or the shutter
release cord.
G.Remove the film by sliding it out slowly, and then count
for approximately 20 sec before beginning to peel chemical
package off. (Polaroid B/W Type 107, preferably speed
1000).
XIDrying a polyacrylamide gel with the Hoefer Scientific SE-540
Slab Gel Dryer
A.Soak the gel to be dried in 5% glycerol for at least 2 h
B.Soak two cellophane sheets in dH2O for about 10 min (avoid
wrinkling).76
C.Place two filter paper pads on top of the dryer's sieve
screen.Cut off corners first with scissors.
D.Lay down first cellophane sheet on filter paper.Lay gel
on, and apply dH2O.
E.Apply top cellophane sheet; remove air bubbles, using dH2O
squirt bottle.
F.Apply "Mylar Sheet".
G.Fold rubber sheet over entire assembly.
H.Open valves on vacuum oven.Turn vacuum pump on.Seal
window shut.Pump to approx. 29 lbs. for 2 min.Then shut
off pump.Shut right valve.Re-pump during drying time as
needed.
I.Turn vacuum oven on to 80° C.
J.Turn Slab Gel Dryer on by setting timer to 2 h (minimum)
for a 1.5 mm polyacrylamide gel.
K.Depressurize by carefully peeling off top rubber sheet.
XII.Permanently Pressing Caseinolytic Agar Gels onto Glass Plate.
A.Lay casein gels on glass on lab counter.
B.Wet filter paper with dH2O and apply to casein gel on
glass.Apply another 8 dry filter sheets on top of that.
C.Apply a large flat surface (i.e. a large glass plate) and a
2-3 kg weight for 15 min.The fragments of casein lysed by
the plasmin will absorb.
D.After 15 min, carefully remove filter paper.
E.Put plates in 60°C oven to dry for 5-10 min.Plates must
be completely clear.
F.Flood plates in Amido Black staining solution for 3-4
minutes.Do not go over time.
G.Amido Black destain overnight.
H.Rinse with tap H2O and stand up in oven to dry 5-10 min.